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Abstract: Topical therapy is the most favored form of treatment for whitening against 
hyperpigmentation and sunburn because it lends itself to self-administration, patient compliance, and 
absence of systemic adverse effects.  However, transdermal delivery of hydrophilic chemicals is 
difficult.  The main purpose of this study is to develop a delivering system of hydrophilic drugs and 
proteins across the skin.  Hydroquinone (HQ), a well-known tyrosinase inhibitor and 
antimelanogenesis compound, and enhanced green fluorescent protein (EGFP) were fused with eleven 
poly-arginine (11R).  Both HQ-11R and EGFP-11R were efficiently delivered in B16 cells, a mouse 
melanoma cell line.  HQ-11R was as effective as HQ alone at inhibiting melanin synthesis in B16 cells.  
EGFP-11R was efficiently delivered into cells of the epidermis with 4-(1-pyrenyl)-butyric acid (PB), a 
counteranion bearing an aromatic hydrophobic moiety, in vivo, but EGFP alone or EGFP-11R without 
PB was not.  Finally, topical application of HQ-11R with PB significantly inhibited UV irradiation-
induced pigmentation in guinea pigs compared with HQ alone.  These results suggest that topical 
therapy using poly-arginine in combination with PB is useful for the delivery of hydrophilic drugs and 
proteins by the transdermal route. 
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Abstract 
Topical therapy is the most favored form of treatment for whitening against 
hyperpigmentation and sunburn because it lends itself to self-administration, patient 
compliance, and absence of systemic adverse effects.  However, transdermal delivery 
of hydrophilic chemicals is difficult.  The main purpose of this study is to develop a 
delivering system of hydrophilic drugs and proteins across the skin.  Hydroquinone 
(HQ), a well-known tyrosinase inhibitor and antimelanogenesis compound, and 
enhanced green fluorescent protein (EGFP) were fused with eleven poly-arginine (11R).  
Both HQ-11R and EGFP-11R were efficiently delivered in B16 cells, a mouse 
melanoma cell line.  HQ-11R was as effective as HQ alone at inhibiting melanin 
synthesis in B16 cells.  EGFP-11R was efficiently delivered into cells of the epidermis 
with 4-(1-pyrenyl)-butyric acid (PB), a counteranion bearing an aromatic hydrophobic 
moiety, in vivo, but EGFP alone or EGFP-11R without PB was not.  Finally, topical 
application of HQ-11R with PB significantly inhibited UV irradiation-induced 
pigmentation in guinea pigs compared with HQ alone.  These results suggest that 
topical therapy using poly-arginine in combination with PB is useful for the delivery of 
hydrophilic drugs and proteins by the transdermal route. 
 
*Abstract
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
1. Introduction 
Transdermal drug delivery has several advantages over other administration routes 
including convenience for the patient, avoidance of hepatic metabolism, and easy 
withdrawal of treatment if necessary [1].  Despite extensive studies of transdermal 
drug delivery, only a few drug formulations are commercially available [1,2].  Almost 
no hydrophilic chemicals and proteins can be delivered by transdermal systems.  One 
reason for this is that the stratum corneum acts as a barrier to exogenous substances [1].  
Another reason is that hydrophilic chemicals and proteins have no ability to penetrate 
cell membranes [3].  To develop transdermal drug delivery systems, these problems 
must be overcome using appropriate physical and chemical means.  To enhance the 
ability of drug molecules to penetrate skin, several methods have been reported [4].  
Occlusive dressing, a technique which hydrates the stratum corneum, is perhaps the 
simplest approach [4,5].  Chemical enhancers such as dimethylsulphoxide (DMSO), 
Azone, oleic acid, propylene glycol, terpenes and terpenoids that improve the diffusion 
coefficient of a substance in the stratum corneum by interacting with intercellular lipids 
have been studied [4,6].  As physical modifications, iontophoresis, which promotes 
skin permeability by using electropotential energy, electroporation, which produces 
small pores on the surface of the stratum corneum by adding electric pulses, 
*Manuscript
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sonophoresis, which utilizes the cavitation of ultrasonic waves, and microneedles which 
produce new permeation routes, have been studied [4,6].  However, both chemical and 
physical enhancers to induce irritation, cause damage, and reduce the skin barrier 
function [4].  Recent studies showed that liposome formulations are effective at 
delivering chemicals and functional molecules through the stratum corneum.  However, 
they probably increase penetration only through the transappendageal route [6,7].  It is 
desirable to deliver therapeutic agents to cells across the stratum corneum while main 
taining the normal skin barrier function.  
Protein transduction system is a widely accepted method of delivering proteins, 
peptides, siRNA and biologically active compounds across the cell membrane by fusing 
with cell-penetrating peptides (CPPs) such as poly-arginine and the protein transduction 
domain of TAT [8-10].  This methodology attracted our attention not only as a means 
of cell biological study but also because of its potential for pharmaceutical vectors [9].  
CPP-fused proteins are rapidly internalized by lipid raft-dependent macropinocytosis 
[11].  After internalization via the macropinocytotic pathway, the proteins are carried 
to macropinosomes, where most of them are then degraded [11].  Recent studies have 
shown that the ability to cross lipid bilayers and gain access to the cell interior of CPPs, 
especially poly-ariginine, is enhanced in the presence of the hydrophobic counter-anion 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
4-(1-pyrenyl)-butyric acid (pyrenebutyrate, PB) [12,13].  The negatively charged 
counteranions and high hydrophobicity of PB can exert a great influence on the 
translocation behavior of arginine peptides in artificial membranes [12,13].  These 
features of the combination of poly-arginine and pyrenebutyrate are thought to be useful 
for the transdermal delivery of hydrophilic chemicals.   
Hydroquinone (HQ) is a tyrosinase inhibitor and a hydrophilic antimelanogenesis 
compound used as an active ingredient in cosmetics and pharmaceuticals [14-16].  In 
the present study, we investigated whether protein transduction using poly-arginine in 
combination with PB was capable of delivering functional hydrophilic molecules and 
proteins into skin. 
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2. Materials and methods 
2.1. Cell Culture 
Mouse B16 melanoma cells (B16-4A5) were provided by the European Collection of 
Cell Culture (ECACC).  Cells were cultured in Dulbecco’s modified Eagle’s medium 
(D-MEM, Life Technologies, Grand Island, NY) with 10% fetal calf serum (Life 
Technologies), 100 U/ml penicillin, 100 U/ml streptomycin and 0.2 % L-glutamine 
(Life Technologies).  Cultures were maintained at 37 °C in 95% air and 5% CO2 in a 
humidified incubator. 
 
2.2. Peptide and HQ-11synthesis  
1) Cys(Npys)-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg- Arg-Arg-Arg-NH2 
Peptide derivatives were assembled using an Applied Biosystems model 433 peptide 
synthesizer with Rink Amide MBHA Resin (0.34 mmol/g, 0.25 mmol) as the starting 
solid support.  The protected peptide resin was treated with a deprotecting reagent 
[TFA-TIS-H2O (95/2.5/2.5/, v/v)] at room temperature for 2 h.  The crude S-Npys 
derivatives were isolated and purified by RP-HPLC.  The purified Npys was used for 
the final disulfide formation procedure. 
2) Cys[(OH)2C6H4S-]-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-NH2·11TFA 
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HQ was conjugated with poly-arginine peptides as shown in Fig. 1.  To an aqueous 
solution (1.2 ml) of Cys(Npys)-11Arg-NH2 (60 mg) was added  
(OH)2C6H4SH(2-mercaptohydroquinone, 3.6 mg, 0.8 eq) with stirring at room 
temperature overnight under an Argon gas atmosphere.  After the reaction was over, 
the reaction mixture was directly subjected RP-HPLC [YMC ODS column (30 x 250 
mm, 0.1%TFA/H2O)].  The desired peptide was obtained as a TFA salt (25 mg), as 
confirmed by RP-HPLC and Mass spectral analysis.  
Cys[(OH)2C6H4S-]-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-NH2·11TFA; 
Mol wt：3232.6 as TFA salt, C75H144N46O14S2 MW:1978.4, MS analysis： m/z 
660.4(M 3H)3, m/z 495.6([M 4H]4), Purity：94.5%. 
 
2.3. Protein/peptide transduction into cells 
The transduction of protein and peptide into cells was carried out as described 
previously [12].  Briefly, cells were plated onto dishes (diameter 3 cm) and incubated 
in D-MEM containing 10% FBS (Life Technologies), 1% penicillin and streptomycin 
for 48 h in a humidified atmosphere containing 5% CO2.  After removal of the medium, 
the cells were washed twice with PBS and incubated with 50 µM 4-(1-pyrenyl)-butyric 
acid (PB, Sigma-Aldrich, St. Louis, MO) in PBS for 2 min at 37 ˚C.  Cells were then 
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replaced with new PBS and protein or peptide dissolved in PBS was added.  After 20 
min, the cells were washed twice with PBS and incubated further in new medium for 
the period indicated. 
 
2.4. Cell Viability Assay 
Cell viability was determined using a CellTiter-Glo® Luminescent Cell Viability 
Assay kit (Promega, Madison, WI) following the manufacturer’s instructions.  After 
the application of HQ and HQ-11R, B16 cells (1×10
3
 per well) seeded onto 96-well 
plates were cultured in D-MEM containing 10% fetal bovine serum, and 1 % penicillin 
and streptomycin for 24 h.  After being washed with PBS, the cells were placed in 
fresh D-MEM and incubated further for 24, 48 and 72 h.  Cell viability was measured 
using a CellTiter-Glo® Luminescent Cell Viability Assay kit with microplate 
luminometer device [MicroLumat Plus LB 96V, Berthold technologies, (Bad Wildbad, 
Germany]]. 
 
2.5. Expression and purification of recombinant forms of EGFP and EGFP-11R 
The recombinant forms of enhanced green fluorescent protein (EGFP) and eleven 
poly-arginine-fused EGFP (EGFP-11R) were produced as described previously [17].  
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2.6. Confocal laser microscopic analysis 
Cells (2 x 10
5
) were plated onto 35-mm-diameter glass-bottomed dishes (Iwaki, 
Tokyo, Japan) coated with laminin and cultured for 48 h.  Cells were preincubated with 
50 µm PB or PBS for 2 min at 37 ˚C.  20 min after the transduction of 5 µM EGFP and 
EGFP-11R, the cells were washed twice with PBS and the medium was replaced with 
D-MEM containing 10% (v/v) calf serum, 1% penicillin and streptomycin.  The EGFP 
signals in living cells were observed using a confocal laser microscope (FV300, 
Olympus, Tokyo, Japan) equipped with a 60 x objective lens at 0.5, 2, 4 and 8 h after 
protein transduction. 
 
2.7. Western blotting analysis   
Western blotting was carried out at high stringency, essentially as described 
previously [18].  The harvested cells were lysed by a sonicator in a boiled buffer 
containing 1% SDS.  The cell lysate (50 µg) was subjected to SDS-PAGE and 
transferred to nitrocellulose membranes (Hybond ECL, Amersham Biosciences).  The 
blots were probed with primary antibodies against tyrosinase (1:100) (Abcam, Tokyo, 
Japan).  Immunoreactive bands were visualized by enhanced chemiluminescence using 
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ECL plus (GE Healthcare UK Ltd, Buckinghamshire, England) and Bio-Rad Versadoc 
(Model 5000, Bio-Rad Laboratories, Inc., Hercules, CA). 
 
2.8. Measurement of melanin contents 
Melanin content was measured described previously [19].  Briefly, B16-4A5 cells 
dissolved in 1ml of 5% Trichloroacetic acid (TCA) were incubated on ice for 10 min.  
After centrifugation, the precipitate was dissolved in 2ml of EtOH-ether (3:1) and 
centrifuged.  The precipitate was resuspended in 2ml of ether, and centrifuged for 10 
min.  Finally, the precipitate was air-dried, and resuspended in 0.5 ml of 2 N NaOH at 
80 ˚C for 1 hr.  The absorbance at 415 nm was measured. 
 
2.9. Topical application of EGFP-11R and EGFP 
The hair from the back of adult guinea pigs (Female Weiser-Maples, SHIMIZU 
Laboratory Supplies, Kyoto, Japan) weighing 450–500 g was removed carefully using 
depilatory cream 24 h before the study.  All procedures of animal experiments were 
approved by the Animal Ethics Committee of Okayama University (OKU-2008019).  
Areas of 4.0 cm
2
 were marked on the dorsal trunk of the animals using a template.  For 
topical treatment of EGFP-11R, PB in propylene glycol [a mixture of 1 µL of PB (50 
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mM) and 99 µL of propylene glycol] was pre-applied on the skin.  After 5 min, 
11R-EGFP [a mixture of 25 µl of 11R-EGFP (50 µM) and 25 µl of propylene glycol] 
was applied to the same region.  As a control, EGFP or EGFP-11R [a mixture of 25 µl 
of 11R-EGFP or EGFP (50 µM each) and 25 µl of propylene glycol] was applied on the 
skin of same guinea pigs.  Skin sections were obtained at 0.5, 2, 4, and 8 h after the 
topical applications with a 3-mm dermapunch (Maruho, Osaka, Japan).  Excised skin 
samples were immediately frozen in Optimal Cutting Temperature compound (Sakura 
Finetek, Japan) and sequentially sectioned at a thickness of 10 µm. The sections were 
fixed with 4% PFA in 0.1 M phosphate buffer (pH 7.4) for 15 min.  After being 
washed with PBS, the sections were incubated with Hoechst 33258 (1 µg/ml) for 5 min, 
and viewed using a confocal microscope (FluoView™ FV300, Olympus, Tokyo, Japan). 
 
2.10. UV-induced pigmentation and topical treatment in vivo 
Hyperpigmentation was induced on the backs of brown guinea pigs by the modification 
of a method as described previously [20].  Four separate areas (2 cm x 3 cm square ) 
on the back were shaved and exposed to UV from Model UVM-57 lamps (Funakoshi, 
Tokyo, Japan),  The total dose of UV was 15 mJ/cm
2
 per day.  Animals were exposed 
five days a week for two consecutive weeks (Fig. 2).  Two days after the last UV 
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irradiation, HQ (a mixture of 50 µl of 1 mM HQ and 50 µl of propylene glycol) was 
applied to the tanning lesion.  HQ-11R and HQ-GLHFPHIYVRD (a mixture of 50 µl 
of 1mM HQ or HQ-peptide and 50µL of propylene glycol) were applied to the tanning 
lesion 5 min after pre-treatment with PB（a mixture of 1 µl of 50 mM PB and 99 µl of 
propylene glycol）.  Guinea pigs were treated with HQ and HQ-peptides once a day, 5 
days a week, for a total of 10 days (Fig. 2).  Three days after the last treatment, the 
animals were sacrificed and skin samples were taken with a 3-mm dermapunch (Maruho, 
Japan).  As a control, the guinea pigs were received 100 µl of propylene glycol. 
 
2.11. Histology study 
Under general euthanasia, skin was removed and fixed in 4% paraformaldehyde in PBS.  
After paraffin processing, paraffin, embedded tissue sections 4.5 µm thick were 
processed for light microscopic examination.  A hematoxylin and eosin (H&E) stain 
was used for studying the general histopathological changes in the skin.  Melanin 
pigments were visualized with Fontana-Masson sliver staining followed by eosin 
background staining as described previously [21].  Melanin-positive cells were 
counted in a 500 x 400 µm area in 20 different fields. 
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2.12. Statistical analysis 
Data are shown as the mean ± S.D.  Data were analyzed using either Student’s t-test to 
compare two conditions or ANOVA followed by planned comparisons of multiple 
conditions, and P < 0.05 was considered to be significant. 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
3. Results 
3.1 Effect of poly-arginine-fused HQ (HQ-11R) with 1-pyrenebutyric acid (PB) on the 
viability of B16-4A5 melanoma cells. 
To investigate the cell toxicity of HQ-11R with PB in B16-4A5, a cell line of mouse 
melanoma, the cells were incubated with each concentration of HQ and HQ-11R.  
When the cells were incubated with 0.5 and 5.0 µM of HQ alone or of HQ-11R with 50 
µM PB, viability was the same as that of the control after 24, 48 and 72 h (Fig. 3A), 
suggesting that neither HQ and nor HQ-11R with PB had cell toxicity when used at 
concentrations of 0.5 and 5 µM.  Viability was significantly inhibited when the cells 
were treated with 50 µM of HQ-11R.  However, 50 µM of HQ also inhibited cell 
viability the same as HQ-11R (Fig. 3A), suggesting the inhibitory effect to be due to 
HQ.   
 
3.2 Inhibitory effect of HQ-11R on melanin content. 
To investigate whether HQ-11R inhibited melanogenesis, B16-4A5 cells were 
incubated with 10, 20 and 30 µM of HQ and HQ-11R and melanin content was 
measured.  Both HQ and HQ-11R dose-dependently inhibited melanin synthesis (Fig. 
3B).  The inhibitory effect of HQ-11R was the same as that of HQ (Fig. 3B).  HQ 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
fused with a control peptide (HQ-GLHFPHIVRD), which consisted of eleven amino 
acids and had no ability to penetrate cells, did not inhibit melanin synthesis when used 
at 10 and 20 µM (Fig. 3B).  HQ –GLHFPHIVRD inhibited melanin synthesis at 30µM 
but its effect was weaker than HQ-11R and HQ alone (Fig. 3B).  The 11R-peptide 
without HQ had no effect on melanin synthesis (Fig. 3B).  HQ is a potent inhibitor of 
tyrosinase, a key enzyme in melanin synthesis, but did not affect the expression or 
degradation of the enzyme [22,23].  Some tyrosinase inhibitors display a 
hypopigmenting effect through post-transcriptional control of the tyrosinase.  Linoleic 
acid decreases the amount of tyrosinase through increased tyrosinase ubiquitination and 
degradation by the proteasome [23].  N-Acetylglucosamine reduced melanin synthesis 
through the inhibition of tyrosinase glycosylation [24].  To investigate the possibility 
that the inhibitory effect of HQ-11R on melanin synthesis was due to the 
post-transcriptional control of tyrosinase, tyrosinase levels were examined in B16-4A5 
cells treated with HQ and HQ-11R.  Neither HQ nor HQ-11R affected the protein level 
(Fig. 3C), suggesting that HQ-11R may inhibit melanin synthesis through the inhibition 
of tyrosinase activity.   
 
3.3 Transdermal delivery of EGFP-11R with PB. 
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Next, the efficiency of the delivery of EGFP fused with 11R (EGFP-11R) in 
B16-4A5 cells was examined.  EGFP without 11R was not observed in the cells (Fig. 
4A).  The signals were observed in almost all of the cells 30 min after the addition of 
EGFP-11R regardless of PB (Fig. 4A).  Strong signals were observed 2, 4 and 8 h after 
the transduction regardless of PB (Fig. 4A).  Preincubation of PB did not affect the 
efficiency of EGFP-11R transduction in the cells (Fig. 4A).  
We next examined the effectiveness of the topical application of EGFP-11R.  When 
EGFP was topically applied, the signals were only observed on the surface of the skin 
(Fig. 4B).  The topical application of EGFP-11R without PB delivered the protein into 
the dermis (Fig. 4B).  However, signals were not observed in the epidermal layer (Fig. 
4B).  Strong signals in the epidermal layer were observed 0.5 and 2 h after the 
application but the signals were faint at 4 and 8 h.  When EGFP-11R was applied with 
PB, strong signals were detected in both epidermis and dermis 0.5 and 2 h after the 
application (Fig. 4B).  Moreover, the signals were spread out more and stronger in 
both layers after 4 and 8 h (Fig. 4B).   
To investigate whether EGFP-11R was delivered in the cells of the epidermis and 
dermis, the skin sections were counter-stained with Hoechst (Fig. 4C).  Most EGFP 
signals did not overlap with Hoechst staining when EGFP-11R was applied without PB, 
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suggesting that 11R-EGFP was delivered in the space of the epidermal layer (Fig. 4C).  
In contrast, when EGFP-11R was applied with PB, the signals overlapped with Hoechst 
staining in the cells of both epidermis and dermis 4 h after the application (Fig. 4C). 
 
3.4 Inhibitory effect of HQ-11R on UV-induced pigmentation in guinea pig skin. 
The whitening effect of HQ-11R was examined using UV-induced pigmentation of 
brown guinea pig skin.  After UV irradiation for 10 days, guinea pigs were topically 
treated with HQ, and HQ-11R and HQ-GLHFPHIYVRD with PB for 10 days (Figs 2 & 
5A).  The treatments did not induce abnormal morphological changes in the epidermis 
and dermis (Fig. 5B).  The HQ application tended to decrease levels of melanin but not 
significant (Fig. 5B & C).  HQ-11R significantly reduced melanin levels in the basal 
cell layer of the epidermis whereas HQ-GLHFPHIYVRD lacking the ability to 
penetrate cells had no effect on melanin levels in the epidermis (Fig. 5C). 
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4. Discussion 
Protein transduction method using CPPs such as 11R is widely accepted as useful for 
the delivery of proteins, peptides and cell-impermeable molecules into cells [25].  
Previous studies have showed the effective transdermal skin delivery of proteins and 
peptides employing CPPs including Tat (Trans-activating transcriptional activator), 
YARA, WLR, and 9R peptides [26-29].  In the present study, we also showed that 
protein transduction method using 11R was valuable for the transdermal delivery of 
EGFP and HQ.  However, EGFP-11R without PB was not delivered into cells of the 
epidermis although signals were observed in the layer.  These results suggest that 
protein transduction using CPPs is capable of increasing the penetration of skin by 
proteins but most proteins delivered topically do not enter or function in cells of the 
epidermis and dermis.  In contrast, EGFP-11R was delivered to cells of the epidermis 
and dermis and HQ-11R reduced melanin levels in the basal cell layer of epidermis 
when applied in combination with 4-(1-pyrenyl)-butyric acid (PB), suggesting that PB 
enhances the intracellular delivery of proteins and hydrophilic molecules delivered 
transdermally.  The molecular mechanism by which CPP-fused proteins cross the cell 
membrane is different with that without PB.   CPP fusion proteins are internalized
 
rapidly by lipid raft-dependent macropinocytosis [11].  In contrast, the negatively 
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charged counteranions and high hydrophobicity of PB can exert a great influence on the 
translocation behavior of arginine peptides in artificial membranes [12,13].  
Endogenous mechanism such as macropinocytosis and endocytosis are not necessary 
for the intracellular delivery of poly-arginine fusion proteins when applied with PB.  
The artificial membrane penetration may be convenient for the transdermal delivery of 
poly-arginine fusion proteins.   
The backbone of PB is a pyrene, a polycyclic aromatic hydrocarbon consisting of 
four fused benzene rings and it contains a hydrophilic carboxylic acid.  The structure is 
similar with benzopyrene, which consists of five benzene rings.  Benzopyrene is found 
in coal tar and cigarette smoke, and shows an evidence of carcinogenicity in lung cells 
[30].  Therefore, PB is misunderstood to have toxicity.  However, a previous study 
showed that PB had no significant cytotoxicity [12].  In the present study, moreover, 
PB did not affect the growth of B16-4A5 nor cause dermatitis in guinea pigs.  These 
results suggest protein transduction using 11R and PB to be safe as a transdermal 
delivery method.  However, further study is needed. 
A previous study showed that bioactive proteins were transdermally delivered by 
non-covalently associated poly-arginine peptides [27].  We also examined whether HQ 
non-covalently associated with 11R was delivered in the dermis and epidermis of guinea 
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pigs when applied with 11R.  However, HQ was not delivered in the skin (data not 
shown).  These results suggest that transdermal delivery by non-covalently associated 
poly-arginine peptides may be suitable for proteins and peptides but not low molecules.   
In conclusion, a topical approach using poly-arginine in combination with PB was 
proven to be beneficial for the delivery of proteins and hydrophilic drugs. HQ-11R is a 
candidate for a skin-whitening agent with the advantages of strong tyrosinase inhibition, 
effective penetration of the skin, and relatively little cytotoxicity. 
 
4. Conclusion 
The present results showed that a poly-arginine (11R) with pre-treatment of PB 
was effective at topical delivering system to enter or function in cells of the epidermis 
and dermis.  It appears that our system can be used to deliver many kinds of proteins 
and whitening-agents into g transcription factors into various cells.  In vivo topical 
protein transduction method with pyrenbutyrate may overcome the disadvantages of 
previous methods and become a promising modality in dermatological field and 
cosmetics industry. 
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Fig. 1.  The schema of HQ-11R synthesis. 
 
Fig. 2.  Time schedule of UV-irradiation and applications of HQ and HQ-11R. 
 
Fig. 3.  Comparison of the inhibitory effect on melanin synthesis between 
hydroquinone (HQ) and eleven poly-arginine-fused HQ (HQ-11R) in B16-4A5 
melanoma cells.  (A) Cell viability was measured by the Cell Titer-Glo Luminescent 
Cell Viability assay.  B16-4A5 cells were treated with 10, 20 and 30 μM of HQ alone 
or HQ-11R in the presence of PB for the periods indicated.  Control cells (Cont.) were 
intact cells.  Data are represented as the mean ± SD.  n=6 each.  (B) Measurement of 
melanin contents in the cells treated with 10, 20 and 30 μM of HQ, HQ-11R, 
HQ-GLHFPHIYBRD and 11R peptide for 24 h.  Data are represented as the mean ± 
SD.  n=6 each.  *P < 0.05, **P < 0.01  (C) Effect of HQ and HQ-11R on tyrosinase 
levels in B16-4A5 cells.  The cells were treated with HQ alone and HQ-11R with PB 
for the periods indicated.  The cells were harvested at each time point and the lysates 
were used for Western blotting. 
 
Captions
Fig. 4.  Transdermal transduction of EGFR-11R with PB.  (A) Time-dependent 
transduction of EGFR-11R with or without PB in B16-4A5 cells.  The cells were 
treated with 1 µM EGFP-11R (EGFP-11R).  After pre-treatment with PB for 5 min, 1 
µM EGFP was added (EGFP-11R + PB).  The signals were observed by confocal 
microscopy at each time point.  Bars = 10 µm.  (B) Time-dependent transdermal 
delivery of EGFP-11R.  EGFP and EGFP-11R with/without PB were applied on the 
skin of guinea pigs.  Skin sections were obtained at each time point and EGFP signals 
were observed with a confocal microscope.  Bars = 200 µm.  (C) The distribution of 
EGFP-11R in the epidermis and dermis of guinea pigs.  EGFP-11R was applied with 
or without PB.  The skin sections were counter-stained with Hoechst 33258 (blue).  
Bars = 50 µm. 
 
Fig. 5.  Inhibitory effect of HQ-11R on UV-induced pigmentation in guinea pig 
skin.  (A) A representative image of the back of the Guinea pigs pre-radiation, 
post-radiation, and pre-treatment and post-treatment with HQ, HQ-non CPP peptide and 
HQ-11R.  Each area is 2cm x 2cm square.  (B) Biopsy specimens from HQ-, 
HQ-11R- or HQ-GLHFPHIYVRD-treated guinea pig skin after 10 days of topical 
application were examined by H.E. staining (upper panel) and Fontana-Masson silver 
staining (lower panel).  Bars = 50 µm.  (C) Number of cells positive for 
Fontana-Masson stain.  The positive cells were counted in a 500 x 400 µm area in 20 
different fields.  *P < 0.01.   
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